FDA committee backs Centocor psoriasis drug

J&J's Centocor won a key vote by an FDA expert committee backing the approval of ustekinumab for moderate to severe psoriasis. But the experts also want to make sure that the developer continues studies exploring possible links between the drug and a heightened risk of cancer and infections. The drug works by targeting the patient's immune system.

"This drug has the potential to be so helpful for patients, and I think it raises an ethical question if we keep it from them," said panel member Lynn A. Drake.

- check out this release
- read the story from Dow Jones

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.